Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Johnson and Johnson
McKinsey
Medtronic
Dow

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

VERDESO Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Verdeso patents expire, and what generic alternatives are available?

Verdeso is a drug marketed by Almirall and is included in one NDA. There are five patents protecting this drug.

This drug has forty-seven patent family members in twenty countries.

The generic ingredient in VERDESO is desonide. There are thirty-one drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the desonide profile page.

Drug patent expirations by year for VERDESO
Drug Prices for VERDESO

See drug prices for VERDESO

Recent Litigation for VERDESO

Identify potential future generic entrants

District Court Litigation
Case NameDate
Delcor Asset Corporation v. Taro Pharmaceutical Industries, Ltd.2016-03-01
New Century Transportation, Inc.2014-06-11

See all VERDESO litigation

Pharmacology for VERDESO
Synonyms for VERDESO
(11ss,16alpha)-11,21-Dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-pregna-1,4-diene-3,20-dione
(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.0;{2,9}.0;{4,8}.0;{13,18}]icosa-14,17-dien-16-one
(4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone
11beta,21-dihydroxy-16alpha,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione
11beta,21-dihydroxy-16alpha,17-isopropylidenedioxypregna-1,4-diene-3,20-dione
11beta,21-dihydroxy-16alpha,17alpha-isopropylidenedioxypregna-1,4-diene-3,20-dione
16-alpha-Hydroxyprednisole-16,17-acetonide
16?,17-[1-Methylethylidenebis(oxy)]-11?,21-dihydroxypregna-1,4-diene-3,20-dione
16alpha-hydroxyprednisole-16,17-acetonide
16alpha-hydroxyprednisolone-16alpha,17-acetonide
16alpha,17-[1-Methylethylidenebis(oxy)]-11beta,21-dihydroxypregna-1,4-diene-3,20-dione (Desonide)
16alpha,17alpha-isopropylidenedioxyprednisolone
638-94-8
638D948
AB01274712_02
AB01274712-01
AB2000229
Apolar
AS-13892
BCP04201
BRD-K21528677-001-03-6
C-22009
CAS-638-94-8
CC-26356
CCG-221279
CHEBI:204734
CHEMBL1201109
CS-2228
D 2083
D-2083
D03696
D2083
DB01260
desfluorotriamcinolone acetonide
Desilux
Desonate
Desonida
Desonida [INN-Spanish]
DESONIDE
Desonide (USAN/INN)
Desonide [USAN:INN:BAN]
Desonidum
Desonidum [INN-Latin]
DesOwen
Desowen (TN)
DSSTox_CID_26756
DSSTox_GSID_46756
DSSTox_RID_81880
DTXSID7046756
EINECS 211-351-6
Flusemidon
GTPL7066
Hamiltoderm
HMS3715P20
HY-B0248
J280872D1O
K016
Locapred
Locapred;Topifug;Tridesilon
MolPort-003-987-087
NCGC00167983-01
NCGC00274065-01
Prednacinolone
Prednisolone-16,17-acetonide, 16-alpha-hydroxy-
Pregna-1,4-diene-3,20-dione, 11,21-dihydroxy-16,17-((1-methylethylidene)bis(oxy))-, (11beta,16alpha)-
Prenacid
Q-101382
Reticus
s1701
SC-17104
SCHEMBL3631
Sterax
Steroderm
TL8004516
Topifug
Tox21_112603
Tox21_112603_1
Tridesilon
Tridesonit
UNII-J280872D1O
Verdeso (TN)
WBGKWQHBNHJJPZ-LECWWXJVSA-N
ZINC4212851
Zotinar

US Patents and Regulatory Information for VERDESO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Almirall VERDESO desonide AEROSOL, FOAM;TOPICAL 021978-001 Sep 19, 2006 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Almirall VERDESO desonide AEROSOL, FOAM;TOPICAL 021978-001 Sep 19, 2006 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Almirall VERDESO desonide AEROSOL, FOAM;TOPICAL 021978-001 Sep 19, 2006 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Almirall VERDESO desonide AEROSOL, FOAM;TOPICAL 021978-001 Sep 19, 2006 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for VERDESO

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0613371 SPC/GB02/033 United Kingdom   Start Trial PRODUCT NAME: FORMOTEROL (OPTIONALLY IN THE FORM OF THE FREE BASE OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, OR A SOLVATE OF SUCH FREE BASE OR SALT ESPECIALLY AS FORMOTEROL FUMARATE DIHYDRATE) AND BUDESONIDE; REGISTERED: SE SE16047, 16048 20000825; UK PL17901/0091 20010515; UK PL17901/0092 20010515
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Colorcon
McKinsey
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.